drugset / Trial / NCT00542464

Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection

NCT00542464

Phase 1 Completed 12 enrolled HiberCell, Inc.
RandomizedParallel-groupTriple-blind

Summary

The study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple-dose (7 day), dose-escalation study assessing the safety, pharmacodynamics, and pharmacokinetics of intravenous Imprime PGG™ Injection in healthy adult subjects.

Timeline

Start
2006-05
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imprime PGG Other / unclassified 1 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 2 mg/kg Intravenous
Comparator Imprime PGG Other / unclassified 4 mg/kg Intravenous

Indications

No indication recorded.